YASMIN TABLET

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

DROSPIRENONE; ETHINYLESTRADIOL

Available from:

BAYER (SOUTH EAST ASIA) PTE LTD

ATC code:

G03AA12

Dosage:

3 mg

Pharmaceutical form:

TABLET, FILM COATED

Composition:

DROSPIRENONE 3 mg; ETHINYLESTRADIOL 0.03 mg

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

BAYER WEIMAR GMBH UND CO KG

Authorization status:

ACTIVE

Authorization date:

2003-06-25

Patient Information leaflet

Yasmin PI_SG_CCDS 14_4 Aug 2014 
1. NAME OF THE MEDICINAL PRODUCT 
Yasmin 0.03mg/3mg film-coated tablets 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION   
21 hormone-containing light yellow film-coated tablets:   
Each film-coated tablet contains 0.03 mg ethinylestradiol, 3mg drospirenone.     

Excipient: Lactose monohydrate 48.170mg. 
For a full lis
t of excipient(s), see section ‘List of excipients’.   

3. PHARMACEUTICAL FORM 

Film-coated tablet. 

The tablet is
light yellow, round with convex faces, one side marked with the letters 
“DO” in a regular hexagon. 

4. CLINICAL PARTICULARS 

4.1 INDICATION 

For oral contraception.     
4.2 DOSAGE AND METHOD OF ADMINISTRATION 
4.2.1 METHOD OF ADMINISTRATION 

Oral use 
4.2.2 HOW TO TAKE YASMIN   

_HOW TO TAKE YASMIN _
Combined  oral  contraceptives,  when  taken  correctly,  have  a  failure  rate  of 
approximately  1%  per  year.  The  failure  rate  may  increase  when  pills  are  missed  or 
taken incorrectly. 

Tablets  must  be  taken  in  the  order  directed  on  the  package  every  day  at  about  the 
same  time  with  some  liquid  as  needed.  One  tablet  is  to  be  taken  daily  for  21 
consecutive days. Each subsequent pack is started after a 7-day tablet-free interval, 
during  which  time  a  withdrawal  bleed  usually  occurs.  This  usually  starts  on  day  2-3 
after the last tablet and may not have finished before
the next pack is started.   
_HOW TO START YASMIN   _

• No preceding hormonal
contraceptive use (in the past month)   
Tablet-
taking has to start on day 1 of the woman’s natural cycle (i.e. the first day of 
her menstrual bleeding). Starting on days 2-5 is allowed, but during the first 

Summary of Product characteristics

Yasmin PI_SG_CCDS 17_21 Mar 2017
1. NAME OF THE MEDICINAL PRODUCT
Yasmin 0.03mg/3mg film-coated tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
21 hormone-containing light yellow film-coated tablets:
Each film-coated tablet contains 0.03 mg ethinylestradiol, 3mg
drospirenone.
Excipient: Lactose monohydrate 48.170mg.
For a full list of excipient(s), see section ‘List of excipients’.
3. PHARMACEUTICAL FORM
Film-coated tablet.
The tablet is light yellow, round with convex faces, one side marked
with the letters
“DO” in a regular hexagon.
4. CLINICAL PARTICULARS
4.1 INDICATION
For oral contraception.
4.2 DOSAGE AND METHOD OF ADMINISTRATION
4.2.1 METHOD OF ADMINISTRATION
Oral use
4.2.2 HOW TO TAKE YASMIN
_HOW TO TAKE YASMIN_
Combined
oral
contraceptives,
when
taken
correctly,
have
a
failure
rate
of
approximately 1% per year. The failure rate may increase when pills
are missed or
taken incorrectly.
Tablets must be taken in the order directed on the package every day
at about the
same time with some liquid as needed. One tablet is to be taken daily
for 21
consecutive days. Each subsequent pack is started after a 7-day
tablet-free interval,
during which time a withdrawal bleed usually occurs. This usually
starts on day 2-3
after the last tablet and may not have finished before the next pack
is started.
_HOW TO START YASMIN_
• No preceding hormonal contraceptive use (in the past month)
Tablet-taking has to start on day 1 of the woman’s natural cycle
(i.e. the first day of
her menstrual bleeding). Starting on days 2-5 is allowed, but during
the first cycle a
barrier method is recommended in addition for the first 7 days of
tablet-taking.
•
Changing
from
a
combined
hormonal
contraceptive
(Combined
oral
contraceptive/COC), vaginal ring, or transdermal patch
The woman should start with Yasmin preferably on the day after the
last
Yasmin PI_SG_CCDS 17_21 Mar 2017
hormone-containing tablet of her previous COC, but at the latest on
the day following
the usual tablet-free or hormone-free tablet interval of her pr